Labshake search
Citations for Leinco Technologies :
1 - 10 of 10 citations for Recombinant Human dipeptidyl peptidase 4 since 2019
Citations are collected from bioRxiv only, the total number of publications could be much larger.
-
bioRxiv - Immunology 2023Quote: ... and treated with recombinant mouse IL-4 (Leinco technologies, Inc. I-207) at a 40ng/ml concentration for 6 hours ...
-
bioRxiv - Immunology 2023Quote: ... allowed to sit for 3 hours and treated with recombinant mouse IL-4 (Leinco technologies, Inc. I-207) for 4 hr ...
-
bioRxiv - Systems Biology 2021Quote: ... Recombinant purified N-terminal domain (NTD) of the SARS-CoV-2 was obtained from Leinco Technologies Inc (Cat #S853 ...
-
bioRxiv - Immunology 2021Quote: Anti-human CD11b (Clone M1/70, Leinco Technologies, Fenton, MO) was conjugated with Alexa Fluor 532 NHS ester according to the manufacturer’s instructions ...
-
bioRxiv - Immunology 2022Quote: ... and goat anti-human PD-L1 (1:50, Leinco Technologies, B560) at 4°C overnight and washed in PBS+0.1% Tween 20 for 5 min three times ...
-
bioRxiv - Immunology 2022Quote: ... and 100 μg anti CTLA-4 (clone 9D9, Leinco Technologies) in volume of 200 μg 1X PBS.
-
bioRxiv - Immunology 2024Quote: ... anti-human CD45 (clones T29/33 and BC8 from Leinco Technologies; clones 2D1 and HI30 from BioLegend).
-
bioRxiv - Immunology 2022Quote: ... Mice were also treated with 4 μg mIFNβ neutralising antibodies (Leinco Technologies Inc). Control groups were treated with either buffer or an IgG isotype control antibody equivalently.
-
bioRxiv - Immunology 2021Quote: ... Mouse anti-mouse IFNAR1 (MAR1-5A3) and isotype control (GIR208, mouse anti-human IFNGR-α chain) were purchased from Leinco Technologies Inc ...
-
bioRxiv - Immunology 2023Quote: ... they were treated with anti-PD-1 anti-CTLA-4 antibodies (clones RMP1-14 and 9H10, respectively, from Leinco Technologies Inc., Fenton, MO, USA): 200 µg ab/injection ...